Patent ID: 8143226
Filing Date: 2012-03-27
Classification: A61K,A61P

Abstract:
1. A method of treating a human breast cancer patient, wherein breast cancer cells in the cancer patient express Her2/neu receptor, comprising the steps of: administering to the patient a therapeutically effective amount of a formulation comprising: (1) a pharmaceutically acceptable carrier; (2) nordihydroguaiaretic acid (NDGA) or pharmaceutically acceptable salts thereof; and (3) doxorubicin, wherein the NDGA and doxorubicin act synergistically to inhibit growth of the breast cancer cells, and wherein doxorubicin and NDGA are administered in amounts below a therapeutically effective amount of either doxorubicin or NDGA when doxorubicin or NDGA are administered alone.